丽珠医药(01513.HK)186个产品获纳入医保目录
格隆汇8月21日丨丽珠医药(01513.HK)发布公告,近日,国家医疗保障局发布了新版《国家基本医疗保险、工伤保险和生育保险药品目录》(医保发〔2019〕46号,以下简称“《医保目录》”)。公司及下属附属公司共有186个产品纳入《医保目录》,其中甲类95个,乙类91个。纳入《医保目录》的主要重点产品有:艾普拉唑肠溶片、注射用醋酸亮丙瑞林微球、参芪扶正注射液、抗病毒颗粒、雷贝拉唑钠肠溶胶囊、注射用伏立康唑、注射用尿促性素、马来酸氟伏沙明片等。
本次退出国家《医保目录》的公司产品共计21个,其中18个产品早已停产停销,退出的在产在销产品2019年1-6月合计销售收入约占公司2019年1-6月营业总收入的4.58%,因此对公司的经营状况不构成重大影响。
公告表示,本次公司多数重点产品,特别是个别独家产品被纳入新版《医保目录》,将会获得医疗机构的积极采购及临床应用,有利于促进该等产品的市场推广,从长期看,将对公司的经营业绩产生积极的影响,同时,因新版《医保目录》的正式执行还需待时日,因此,短期内尚不会对公司的经营业绩构成重大影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.